Temodal (TMZ) [temozolomide] in Concomitant Radiochemotherapy Followed by Sequential TMZ Chemotherapy in Newly Diagnosed Glioblastoma Multiforme Patients - an Observational Program

Trial Profile

Temodal (TMZ) [temozolomide] in Concomitant Radiochemotherapy Followed by Sequential TMZ Chemotherapy in Newly Diagnosed Glioblastoma Multiforme Patients - an Observational Program

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Nov 2014

At a glance

  • Drugs Temozolomide (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions
  • Sponsors Merck Sharp & Dohme; Schering-Plough
  • Most Recent Events

    • 17 Nov 2010 Actual initiation date changed from May 2007 to Apr 2007 as reported by ClinicalTrials.gov.
    • 29 Jan 2010 Actual end date (April 2009) added as reported by ClinicalTrials.gov.
    • 29 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top